Immune reconstitution and clinical recovery following anti-CD28 antibody (TGN1412)-induced cytokine storm.

ABSTRACT: Cytokine storm can result from cancer immunotherapy or certain infections, including COVID-19. Though short-term immune-related adverse events are routinely described, longer-term immune consequences and sequential immune monitoring are not as well defined. In 2006, six healthy volunteers received TGN1412, a CD28 superagonist antibody, in a first-in-man clinical trial and suffered from cytokine storm. After the initial cytokine release, antibody effect-specific immune monitoring started on Day + 10 and consisted mainly of evaluation of dendritic cell and T-cell subsets and 15 serum cytokines at 21 time-points over 2 years. All patients developed problems with concentration and memory; three patients were diagnosed with mild-to-moderate depression. Mild neutropenia and autoantibody producti

SUBMITTER: Panoskaltsis N 

PROVIDER: S-EPMC7543968 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature